Literature DB >> 20480516

Safety of the long-term use of proton pump inhibitors.

Alan B R Thomson, Michel D Sauve, Narmin Kassam, Holly Kamitakahara.   

Abstract

The proton pump inhibitors (PPIs) as a class are remarkably safe and effective for persons with peptic ulcer disorders. Serious adverse events are extremely rare for PPIs, with case reports of interstitial nephritis with omeprazole, hepatitis with omeprazole and lansoprazole, and disputed visual disturbances with pantoprazole and omeprazole. PPI use is associated with the development of fundic gland polyps (FGP); stopping PPIs is associated with regression of FGP. In the absence of Helicobacter pylori infection, the long-term use of PPIs has not been convincingly proven to cause or be associated with the progression of pre-existing chronic gastritis or gastric atrophy or intestinal metaplasia. Mild/modest hypergastrinemia is a physiological response to the reduction in gastric acid secretion due to any cause. The long-term use of PPIs has not been convincingly proven to cause enterochromaffin-like cell hyperplasia or carcinoid tumors. PPIs increase the risk of community acquired pneumonia, but not of hospital acquired (nosocomial) pneumonia. There is no data to support particular care in prescribing PPI therapy due to concerns about risk of hip fracture with the long-term use of PPIs. Long-term use of PPIs does not lead to vitamin B12 deficiencies, except possibly in the elderly, or in persons with Zollinger-Ellison Syndrome who are on high doses of PPI for prolonged periods of time. There is no convincingly proven data that PPIs increase the risk of Clostridium difficile-associated diarrhea in persons in the community. The discontinuation of PPIs may result in rebound symptoms requiring further and even continuous PPI use for suppression of symptoms. As with all medications, the key is to use PPIs only when clearly indicated, and to reassess continued use so that long-term therapy is used judiciously. Thus, in summary, the PPIs are a safe class of medications to use long-term in persons in whom there is a clear need for the maintenance of extensive acid inhibition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20480516      PMCID: PMC2874135          DOI: 10.3748/wjg.v16.i19.2323

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  140 in total

1.  Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy.

Authors:  H Koop; M G Bachem
Journal:  J Clin Gastroenterol       Date:  1992-06       Impact factor: 3.062

2.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

3.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

4.  Effect of long-term omeprazole treatment on antral G and D cells in children.

Authors:  D S Pashankar; D M Israel; G P Jevon; A M Buchan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2001-11       Impact factor: 2.839

5.  Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools.

Authors:  Manfred Hauben; Sebastian Horn; Lester Reich; Muhammad Younus
Journal:  Int J Infect Dis       Date:  2007-03-02       Impact factor: 3.623

6.  Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis.

Authors:  T T Wu; S Kornacki; A Rashid; J H Yardley; S R Hamilton
Journal:  Am J Surg Pathol       Date:  1998-03       Impact factor: 6.394

Review 7.  Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm.

Authors:  Paul Moayyedi; Ann Cranney
Journal:  Am J Gastroenterol       Date:  2008-10       Impact factor: 10.864

8.  Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment.

Authors:  E Solcia; R Fiocca; N Havu; A Dalväg; R Carlsson
Journal:  Digestion       Date:  1992       Impact factor: 3.216

9.  Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.

Authors:  S Bruley des Varannes; P Levy; S Lartigue; F Dellatolas; M Lemaire; J P Galmiche
Journal:  Aliment Pharmacol Ther       Date:  1994-06       Impact factor: 8.171

10.  Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole.

Authors:  Dincer Yildizdas; Hacer Yapicioglu; Hayri Levent Yilmaz
Journal:  J Crit Care       Date:  2002-12       Impact factor: 3.425

View more
  69 in total

1.  Calcium gluconate supplementation is effective to balance calcium homeostasis in patients with gastrectomy.

Authors:  M Krause; J Keller; B Beil; I van Driel; J Zustin; F Barvencik; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2014-11-13       Impact factor: 4.507

Review 2.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

Review 3.  Reflux and aerodigestive tract diseases.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Daniela Paccagnella; Robert P Takes; Alessandra Rinaldo; Carl E Silver; Julia A Woolgar; Michael L Hinni; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-07       Impact factor: 2.503

Review 4.  Pharmacologic options in the management of upper gastrointestinal bleeding: focus on the elderly.

Authors:  Moe Htet Kyaw; Francis Ka Leung Chan
Journal:  Drugs Aging       Date:  2014-05       Impact factor: 3.923

5.  Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro-oesophageal reflux disease: a randomized, double-blind, controlled, multicentre trial.

Authors:  Jasper Hein
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

6.  Proton pump inhibitors: use, misuse and concerns about long-term therapy.

Authors:  T P Rakesh
Journal:  Clin J Gastroenterol       Date:  2011-02-18

7.  Early referral for 24-h esophageal pH monitoring may prevent unnecessary treatment with acid-reducing medications.

Authors:  David A Kleiman; Matthew J Sporn; Toni Beninato; Yasmin Metz; Carl Crawford; Thomas J Fahey; Rasa Zarnegar
Journal:  Surg Endosc       Date:  2012-12-12       Impact factor: 4.584

Review 8.  The role of the gastrointestinal tract in calcium homeostasis and bone remodeling.

Authors:  J Keller; T Schinke
Journal:  Osteoporos Int       Date:  2013-03-28       Impact factor: 4.507

9.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

10.  The rOmp22-HpaA fusion protein confers protective immunity against helicobacter pylori in mice.

Authors:  Xueyong Huang; Bianli Xu; Guangcai Duan; Chunhua Song
Journal:  Curr Microbiol       Date:  2013-05-30       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.